HLA-A and neoplasm: The treatment regime was as follows: HLA-A*02:01-restricted GPC3144–152 or CMV495–503 peptide emulsified with IFA (50 μg/100 μl) was injected into a tumor, and, 2 h later, HLA-A*02:01-restricted GPC3144–152 or CMV495–503 peptide-specific human CTLs (1 × 107 cells/100 μl) were injected into the tumor.